Share

August 06, 2013; 81 (6) Article

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Amit Bar-Or, Mark S. Freedman, Marcelo Kremenchutzky, Françoise Menguy-Vacheron, Deborah Bauer, Stefan Jodl, Philippe Truffinet, Myriam Benamor, Scott Chambers, Paul W. O’Connor
First published July 12, 2013, DOI: https://doi.org/10.1212/WNL.0b013e31829e6fbf
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1698

Share

Article Information

vol. 81 no. 6 552-558
DOI: 
https://doi.org/10.1212/WNL.0b013e31829e6fbf
PubMed: 
23851964
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 8, 2013
  • Accepted in final form April 24, 2013
  • First Published July 12, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Amit Bar-Or, MD,
    2. Mark S. Freedman, MD,
    3. Marcelo Kremenchutzky, MD,
    4. Françoise Menguy-Vacheron, PhD,
    5. Deborah Bauer, MS,
    6. Stefan Jodl, MD,
    7. Philippe Truffinet, MD,
    8. Myriam Benamor, MD,
    9. Scott Chambers, PhD and
    10. Paul W. O’Connor, MD
  1. Amit Bar-Or, MD,
    2. Scientific Advisory Boards:

    1. Diogenix, Advisor, Scientific Board, 2008- Ono Pharmacia, Advisor, Scientific Board, 2008- Receptos, Advisor, Scientific Board, 2011 - Roche, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Guthy Jackson Greater Good Foundation, NMO Research and Clinical Care Consortium, Scientific Advisor, 2009-

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Board Member, 2008- Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Novartis 2. EMD Serono 3. Amplimmune

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Mark S. Freedman, MD,
    3. Scientific Advisory Boards:

    1. Actelion, sanofi-aventis/Genzyme, Novartis, Merck Serono, Bayer, BiogenIdec, Roche, Celgene, Opexa, Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck Serono, Novartis, Sanofi-Aventis/Genzyme

    Editorial Boards:

    1. J Neurol Sci Multiple Sclerosis Multiple Sclerosis International Int J MS Care

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Celgene, Opexa, Novartis, Sanofi, Bayer, Merck Serono, Kirin, BiogenIdec

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Bayer, Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Marcelo Kremenchutzky, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Funding for travel or speaker honoraria from (1) Biogen, (2) Bayer, (3) Teva, (4) Genzyme - sanofi, (5) Novartis, (6) serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Biogen, (2) Bayer, (3) Teva, (4) Genzyme - Sanofi, (5) Novartis, (6) Serono

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme, (2) Cell Gene, (3) Biogen, (4) Bayer, (5) Teva, (6) Sanofi, (7) Novartis, (8) Serono

    Research Support, Government Entities:

    1. (1) CIHR, co-investigator, from: 2011-04-01 to: 2016-03-31

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) MS Society of Canada

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Françoise Menguy-Vacheron, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. 1) Employee of Genzyme, a Sanofi company , Clinical research director in clinical pharmacology

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Deborah Bauer, MS,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Sanofi, Biostatistician

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Stefan Jodl, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Sanofi, Clinical Study Director (CSD)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Philippe Truffinet, MD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Genzyme/Sanofi, Clinical Research Director

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Salary as employee

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. Stocks, as employee

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Myriam Benamor, MD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Scott Chambers, PhD and
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Employee of Fishawack Communications Ltd, contracted to provide editorial services to Sanofi, funded by Genzyme, a Sanofi company.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Paul W. O’Connor, MD
    11. Scientific Advisory Boards:

    1. Novartis Fingolimod Steering Committee--member--2007-present Teriflunomide Steering Committee ( sanofi aventis)--chairman--2006-present Bayer BEYOND study steering committee--chairman--2007-2009 BRAVO (laquinimod) study DMC--chairman--2007-present Genentech advisory board--member Roche advisory board Receptos advisory board Actelion advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. 1 Biogen Idec-ECTRIMS meeting Dusseldorf--2009--presentations of data from two studies 2 Teva--Meeting in London--advise and present data on safety of MS drugs--2009 3 Advisory board meeting in Montreal 2010 4 Advisory board meeting in Toronto 2013

    Editorial Boards:

    1. 1 MS Journal. Editorial advisory board. July 2012--March 2013

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec consultant 2007-2012 Actelion consultant 2010 Bayer Consultant 2007-2009 EMD Serono Consultant 2009-11 Teva Consultant 2007-2013 Genentech Consultant 2007-2008 Sanofi Genzyme Consultant 2002-2013 Novartis Consultatn 2005-2013 Warburg Pincus Consultant 2009

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1 Bayer--study grant support for BEYOND study--2006-8 2 Novartis--study grant support for FREEDOMS, TRANSFORMS and INFORMS study--2006-2012 3 BIOMS--study grant support 2006-9 4 Sanofi Aventis-grant supprot for TEMSO, phase 2 , CIS and nerispirdine studies 5 ROCHE; grant supprot for phase 2 OCRELIZUMAB study 6 Biogen Idec: grant support for ASCEND and JEMS study 7 Roche grant support for OPERA and ORATORIO studies 8 Novartis support for INFORMS study of PPMS

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Scientific and Clinical Advisor to to the MS Society of Canada. 2008-2013 (ongoing)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From McGill University (A.B.-O.), Montreal, Quebec, Canada; University of Ottawa and the Ottawa Hospital Research Institute (M.S.F.), Ottawa, Ontario, Canada; Western University (M.K.), London, Ontario, Canada; Genzyme, a Sanofi company (F.M.-V., P.T.), Chilly Mazarin, France; Sanofi (D.B.), Bridgewater, NJ; Kleinmachnow (S.J.), Germany; Sanofi (M.B.), Chilly Mazarin, France; Fishawack Communications Ltd. (S.C.), Abingdon, UK; and University of Toronto (P.W.O.), Toronto, Ontario, Canada.
  1. Correspondence to Dr. Bar-Or: amit.bar-or{at}mcgill.ca
View Full Text

Article usage

Article usage: July 2013 to April 2021

AbstractFullPdfSource
Jul 2013754170Highwire
Aug 2013188997120Highwire
Sep 20132985337Highwire
Oct 20132167747Highwire
Nov 20131316227Highwire
Dec 20131577027Highwire
Jan 20141134827Highwire
Jan 201414422pmc
Feb 2014562821Highwire
Mar 2014673719Highwire
Apr 2014851515Highwire
May 2014682115Highwire
Jun 2014431610Highwire
Jul 2014322517Highwire
Aug 2014361110Highwire
Sep 2014441517Highwire
Oct 201425148Highwire
Nov 2014381113Highwire
Dec 201432115Highwire
Jan 201544105Highwire
Jan 201502511pmc
Feb 201525114Highwire
Feb 20150188pmc
Mar 201533105Highwire
Mar 201502613pmc
Apr 201529106Highwire
Apr 20150259pmc
May 20151335Highwire
May 20150186pmc
Jun 201519128Highwire
Jun 201503411pmc
Jul 201524186Highwire
Jul 20150221pmc
Aug 201538912Highwire
Aug 20150138pmc
Sep 20153398Highwire
Sep 201502613pmc
Oct 2015221212Highwire
Oct 20150377pmc
Nov 201526118Highwire
Nov 201503018pmc
Dec 201518138Highwire
Dec 201505012pmc
Jan 20162357Highwire
Jan 201602210pmc
Feb 20164183Highwire
Feb 201601710pmc
Mar 2016381511Highwire
Mar 20160248pmc
Apr 201621134Highwire
Apr 20160132pmc
May 20161787Highwire
May 20160149pmc
Jun 20162756Highwire
Jun 201601812pmc
Jul 20161764Highwire
Jul 20160136pmc
Aug 20165834Highwire
Aug 20160215pmc
Sep 20164165Highwire
Sep 20160226pmc
Oct 201638413Highwire
Oct 20160208pmc
Nov 20163144Highwire
Nov 2016085pmc
Dec 20167226Highwire
Dec 2016091pmc
Jan 20172863Highwire
Jan 201702712pmc
Feb 201732158Highwire
Feb 20170238pmc
Mar 20172974Highwire
Mar 20170274pmc
Apr 20174576Highwire
Apr 2017101831pmc
May 2017551210Highwire
May 201792033pmc
Jun 20173423Highwire
Jun 201771422pmc
Jul 20171923Highwire
Jul 201771526pmc
Aug 20172585Highwire
Aug 201731122pmc
Sep 20172222Highwire
Sep 201731114pmc
Oct 20173313Highwire
Oct 2017102322pmc
Nov 20173954Highwire
Nov 201752437pmc
Dec 201713102Highwire
Jan 201826303Highwire
Feb 201837192Highwire
Mar 201825138Highwire
Apr 201830142Highwire
Apr 2018152039pmc
May 201832236Highwire
Jun 2018231410Highwire
Jun 201892643pmc
Jul 201825207Highwire
Aug 201818217Highwire
Aug 20184830pmc
Sep 201835282Highwire
Oct 201879226Highwire
Nov 20182196Highwire
Dec 20182294Highwire
Jan 201931198Highwire
Feb 201919135Highwire
Mar 2019152612Highwire
Apr 2019232913Highwire
May 2019253111Highwire
Jun 2019232911Highwire
Jul 201966299Highwire
Aug 20192013710Highwire
Sep 2019366227Highwire
Oct 2019320383Highwire
Nov 20191948410Highwire
Dec 2019229304Highwire
Jan 2020169404Highwire
Feb 2020171315Highwire
Mar 2020169467Highwire
Apr 2020851510Highwire
May 2020841914Highwire
Jun 2020892215Highwire
Jul 20201992012Highwire
Aug 2020101209Highwire
Sep 202015267Highwire
Oct 202052412Highwire
Nov 202074921Highwire
Dec 2020264213Highwire
Jan 2021153934Highwire
Feb 2021113036Highwire
Mar 2021132420Highwire
Apr 2021124530Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Topics Discussed

Alert Me